JP2023527059A - 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法 - Google Patents

関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法 Download PDF

Info

Publication number
JP2023527059A
JP2023527059A JP2022573217A JP2022573217A JP2023527059A JP 2023527059 A JP2023527059 A JP 2023527059A JP 2022573217 A JP2022573217 A JP 2022573217A JP 2022573217 A JP2022573217 A JP 2022573217A JP 2023527059 A JP2023527059 A JP 2023527059A
Authority
JP
Japan
Prior art keywords
antibody
subject
rheumatoid arthritis
seq
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573217A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021240369A5 (https=
JP2023527059A5 (https=
Inventor
ハーラルト・ブルクハルト
インカ・アルブレヒト
Original Assignee
サノフィ・バイオテクノロジー
オイゲン・ファイスト
ペーア－マルテ・アリーズ
ジルケ・ジン
ハーラルト・ブルクハルト
ハンス－ペーター・トーニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ・バイオテクノロジー, オイゲン・ファイスト, ペーア－マルテ・アリーズ, ジルケ・ジン, ハーラルト・ブルクハルト, ハンス－ペーター・トーニー filed Critical サノフィ・バイオテクノロジー
Publication of JP2023527059A publication Critical patent/JP2023527059A/ja
Publication of JPWO2021240369A5 publication Critical patent/JPWO2021240369A5/ja
Publication of JP2023527059A5 publication Critical patent/JP2023527059A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022573217A 2020-05-26 2021-05-25 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法 Pending JP2023527059A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063030065P 2020-05-26 2020-05-26
US63/030,065 2020-05-26
US202163155125P 2021-03-01 2021-03-01
US63/155,125 2021-03-01
EP21315087.3 2021-05-25
EP21315087 2021-05-25
PCT/IB2021/054546 WO2021240369A1 (en) 2020-05-26 2021-05-25 Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same

Publications (3)

Publication Number Publication Date
JP2023527059A true JP2023527059A (ja) 2023-06-26
JPWO2021240369A5 JPWO2021240369A5 (https=) 2024-06-03
JP2023527059A5 JP2023527059A5 (https=) 2024-06-03

Family

ID=76197513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573217A Pending JP2023527059A (ja) 2020-05-26 2021-05-25 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法

Country Status (7)

Country Link
US (1) US20230174657A1 (https=)
JP (1) JP2023527059A (https=)
AU (1) AU2021281119A1 (https=)
BR (1) BR112022024020A2 (https=)
CA (1) CA3180369A1 (https=)
IL (1) IL298088A (https=)
WO (1) WO2021240369A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
AU2019329958B2 (en) * 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL SIGNALING TECHNOLOGY [ONLINE]，JAK/STAT：IL-6受容体シグナル伝達, 公開日：2012年, [検索日：2026., JPN6026006265, ISSN: 0005802014 *
医薬・生活衛生局医薬品審査管理課[ONLINE], 審議結果報告書［販売名］ケブザラ皮下注150 MGシリンジ、同皮, JPN6025022001, ISSN: 0005802013 *

Also Published As

Publication number Publication date
AU2021281119A1 (en) 2023-02-02
BR112022024020A2 (pt) 2023-04-04
US20230174657A1 (en) 2023-06-08
CA3180369A1 (en) 2021-12-02
IL298088A (en) 2023-01-01
WO2021240369A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
US20260027202A1 (en) Treatment of rheumatoid arthritis with an il-6r antibody
US9943594B2 (en) Methods for the treatment of rheumatoid arthritis
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
US20250333522A1 (en) Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP7542543B2 (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP2023527059A (ja) 関節リウマチを治療するためのインターロイキン６受容体に対する抗体を含む組成物およびその使用方法
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224